Cambridge, United Kingdom · Founded 2004 · Privately Held (backing)
Developer of chimeric antigen receptor T-cell therapy and antibody-based immune therapeutics designed to treat cancer. Biosceptre is based in Cambridge, United Kingdom and was founded in 2004. Its last reported valuation was $432 million in Feb 2024. It has raised $52.8 million.
Last reported valuation
$431.9M
Oct 2026
Priced at
—
Total raised
$52.8M
Last round
—
Team — not yet on record
No current team members for Biosceptre are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Biosceptre with a free account
·Watch Biosceptre: the Monday email on marks, rounds and moves
